Ann: Immutep reports positive TACTI-002 data, page-35

The previously reported ORR was 41%, which has now risen to 47% as the trial data matured.

Tacti looks to be wedging its foot further in the door. Merck will almost certainly expand the remaining cohorts based on this and patient recruitment should accelerate too.

Looking forward to getting more colour and insights when they hold the webcast.


Webcast Details The Company will also present this interim TACTI-002 data and provide a further update on its clinical programs in a global webcast.


* Date & Time: Wednesday, February 26, 2020, 8:00 am Australian Eastern Daylight Time / Tuesday, February 25, 2020, 4:00 pm US Eastern Daylight Time

* Register: Interested parties can register via a link to the webcast on the Company’s website or via the following link: https://fnn.webex.com/fnn/onstage/g.php?MTID=e11208a0ff7fcccaca4d5e4b8a14e988f

* Questions: Investors are invited to submit questions in advance via [email protected].

* A replay of the webcast will also be available at www.immutep.com from the day after the event.

.